Clinical trials: Resistant Major Depressive Disorder
Depression, Major Depressive Disorder
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
Background: Most drugs that treat mood disorders take a long time to work. Ketamine works within hours. A dose can last for a week or more. Certain receptors in the brain might help ketamine work.
- Conditions
- Depression, Major Depressive Disorder, Major Depression
- Trial name
- NCT03973268
- Testing
- Arm 1, 2, 3 device interventions, Arm 2 Interventions, Arm 1, 2, 3 drug Interventions
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Episode, Major Depressive Disorder
Patient-oriented Randomized Pragmatic Feasibility Trial With rTMS in Depression and Anxiety
This trial compares intermittent theta-burst stimulation (iTBS) to low frequency repetitive transcranial magnetic stimulation (LFR) in regards to depression and anxiety outcomes in 100 patients with treatment resistant depression…
- Trial name
- PORT (NCT05028738)
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of British Columbia
Major Depression
Deep Brain Stimulation of the Superolateral Branch of the Medial Forebrain Bundle (slMFB) for the Treatment of Refractory Major Depression
The investigators will investigate in a sham controlled staggered onset design antidepressant effects and safety of deep brain stimulation (DBS) to the superolateral branch of the main medial forebrain bundle (slMFB).
- Trial name
- FORESEEII (NCT01778790)
- Testing
- Deep Brain Stimulation with Activa PC Multi-program Neurostimulator
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- University Hospital, Bonn
Major Depressive Disorder, Treatment Resistant Depression
Antidepressant Effects of Nitrous Oxide
To evaluate the acute and sustained antidepressant effects of nitrous oxide in people with major depressive disorder; and further evaluate these effects by identifying the optimal dose and regimen to guide current practice, and…
- Trial name
- NCT05357040
- Testing
- Nitrous oxide gas for inhalation
- Where
- 2 sites in United States, Australia
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Chicago
Treatment Resistant Depression (TRD)
Ketamine Biomarker Validation
An EEG-based biomarker will be developed for the effects of ketamine infusion in patients with Depression. The effects of ketamine infusion on Depression symptoms and EEG signals will be analyzed.
- Trial name
- NCT07307768
- Testing
- Ketamine (0.25 mg/kg), Ketamine (0.5 mg/kg), Ketamine (0.75 mg/kg)
- Where
- United States
- Sponsor
- Soterix Medical
Major Depressive Disorder
Transcranial Direct Current Stimulation as an Augmenting Intervention for Major Depression
Transcranial direct current stimulation (tDCS) is a noninvasive method to activate or de-activate neurons in superficial regions of the brain through the induction of weak electric currents in the brain tissue delivered by two…
- Trial name
- NCT01450150
- Testing
- Transcranial Direct Current Stimulation
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Douglas Mental Health University Institute
Treatment-resistant Depression
Efficacy Study of Deep Brain Stimulation in Patients With Treatment Resistant Major Depression
The primary objective of this multicenter, randomized, sham-controlled, double blind (patient and observer blinded) clinical trial is to assess the antidepressant effect of Deep Brain Stimulation (DBS) in patients with treatment…
- Trial name
- FORESEE III (NCT03653858)
- Testing
- Vercise GEVIA deep brain stimulation (DBS) system
- Where
- 2 sites in France, Germany
- Volunteers
- 46 people
- Sponsor
- University Hospital Freiburg
Treatment Resistant Depression (TRD), Late Life Depression (LLD)
Lumateperone for Late-Life Depression
The purpose of this research study is to examine how well a medication called lumateperone (Caplyta) works to relieve depression in older adults with treatment-resistant depression. Lumateperone (Caplyta) is approved by the U.S.
- Conditions
- Treatment Resistant Depression (TRD), Late Life Depression (LLD), Depression / Major Depressive Disorder
- Trial name
- IRL Grey-C (NCT07623135)
- Testing
- Lumateperone
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Eric Lenze
Major Depressive Disorder, Depression
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin
The purpose of this study is to see if one or two doses of psilocybin is more effective in relieving depressive symptoms in patients with treatment-resistant depression (TRD).
- Conditions
- Major Depressive Disorder, Depression, Treatment-Resistant Depression, Mood Disorders
- Trial name
- PSI-1V2 (NCT06341426)
- Testing
- Single Psychedelic Dose Psilocybin, Two Psychedelic Doses Psilocybin
- Where
- 2 sites in Canada
- Volunteers
- 92 people
- Sponsor
- University Health Network, Toronto
Depression
Safety and Efficacy of EVT 101 in Treatment-Resistant Depression
This study is a 4-week, randomized, double-blind, parallel-group, placebo-controlled monotherapy study in patients with treatment-resistant major depression.
- Trial name
- NCT01128452
- Testing
- EVT 101
- Where
- 14 sites in United States
- Volunteers
- 8 people
- Sponsor
- Janssen Research & Development, LLC
Treatment Resistant Depression
COpenhagen Magnetic Personalized Accelerated Brain Circuit Therapy for Treatment Resistant Depression
The CoMPACT trial is a randomized double-blinded sham-controlled study aimed at testing a novel accelerated and personalized transcranial Magnetic Stimulation (TMS) treatment for patients with Treatment Resistant Depression…
- Trial name
- CoMPACT (NCT06895863)
- Testing
- MagVenture XP Orange Stimulator and active side of MagVenture COOL-B65 coil., Device: MagVenture XP Orange Stimulator and active side of MagVenture COOL-B65 coil.
- Where
- 3 sites in Denmark
- Volunteers
- 78 people
- Sponsor
- Danish Research Centre for Magnetic Resonance
Treatment-resistant Depression
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression
The study aims to investigate the safety and efficacy of oral psilocybin administered under supportive conditions in treatment-resistant major depression (TRD).
- Trial name
- EPIsoDE (NCT04670081)
- Testing
- Psilocybin, Nicotinamide
- Where
- 2 sites in Germany
- Volunteers
- 144 people
- Sponsor
- Central Institute of Mental Health, Mannheim
Major Depressive Disorder
D-cycloserine for Major Depressive Disorder
For many depression patients treatment changes are required, including switching to another antidepressant and addition of a second antidepressant or a non-antidepressant agent ("augmentation").
- Trial name
- NCT00408031
- Testing
- D-cycloserine
- Where
- 2 sites in Israel
- Volunteers
- 26 people
- Sponsor
- Herzog Hospital
Major Depressive Disorder
Inflammation and Electroconvulsive Therapy
The purpose of this study is to explore whether electroconvulsive therapy (ECT) accidentally leads to a side effect of brain inflammation.
- Trial name
- NCT02095639
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Centre for Addiction and Mental Health
Suicidal Ideation
Ketamine For Suicidal Ideation
This study will examine the effects of Intravenous (IV) ketamine both in an outpatient population and with subjects on the inpatient unit with suicidal ideation (SI).
- Trial name
- NCT01507181
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- James Murrough
Depression
SubGenual CG25 Deep Brain Stimulation in Severe Resistant Depression
Despite the availability of several treatments, a number of patients with major depression are refractory to therapeutical approaches and therefore suffer from chronic handicap.
- Trial name
- CG25 (NCT01834560)
- Where
- France
- Volunteers
- 5 people
- Sponsor
- University Hospital, Grenoble
Major Depression
Use of Risperidone in ECT for Treatment Resistant Depression
The purpose of this study is to determine if the combination of risperidone and ECT improves a patient's response in depression compared to ECT alone.
- Trial name
- NCT00203723
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of California, Los Angeles
Depression, Major Depressive Disorder
Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression - A Pilot Study
The purpose of this study is to determine whether an oxytocin ad-on, or oxytocin and tibolone ad-on can induce a response to antidepressants in patients with treatment resistant depression.
- Trial name
- NCT01239888
- Testing
- Oxytocin, Oxytocin and Tibolone
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- The Alfred
Major Depressive Disorder
Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression
Aripiprazole has been approved by the FDA for augmenting ineffective/partially effective oral antidepressant therapy in patients suffering from major depression. The mechanism by which this augmentation is achieved is not known.
- Trial name
- NCT00953745
- Testing
- Escitalopram, Aripiprazole
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Treatment Resistant Depression
Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression
The present study has been designed to compare the efficacy and safety of augmentation of SSRIs with Amantadine vs Pramipexole vs the recommended Quetiapine augmentation in Treatment-Resistant Depression (TRD) and correlate the…
- Trial name
- APQ-TRD (NCT04936126)
- Testing
- Quetiapine, Amantadine, Pramipexole
- Where
- India
- Volunteers
- 150 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar